A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Inclusion Criteria: * Diagnosis of sJIA according to the International League of Associations for Rheumatology (ILAR) classification * History of inadequate clinical response (in the opinion of the treating physician) to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids * If a participant has received previous treatment with any biologic agents other than tocilizumab, these must have been discontinued according to the timelines defined by protocol prior to the baseline visit * Participants currently receiving tocilizumab by the intravenous (IV) route of administration and with well-controlled disease do not require a period of discontinuation of IV tocilizumab and should have their first dose of SC tocilizumab administered on the date that their next IV tocilizumab infusion would be due * Concurrent treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs) including methotrexate (MTX), NSAIDs, and oral corticosteroids are permitted at the discretion of the investigator * Participants of reproductive potential must be willing to use highly effective contraceptive methods Exclusion Criteria: * Prior discontinuation of IV tocilizumab because of inadequate clinical response or safety events (including hypersensitivity) * Participants with poorly controlled disease (in the opinion of the treating physician) despite current treatment with IV tocilizumab * sJIA that is well controlled by any treatment agent other than tocilizumab (Juvenile Arthritis Disease …